REPEAT - Champignon Appoints Former President of Red Bull Canada to Special Advisory Committee
16 April 2020 - 2:00PM
Champignon Brands Inc. (“
Champignon” or the
“
Company”)
(CSE: SHRM) (FWB: 496) (OTC:
SHRMF), a human optimization sciences company focused on
applying novel and natural treatment protocols to address a broad
range of disorders and deficiencies with an emphasis on psychedelic
medicine, has further bolstered its pharmaceutical, nutraceutical
and CPG marketing/distribution competencies via the appointment of
the former President of Red Bull Canada, Mr. Jim Bailey, to its
Special Advisory Committee. Mr. Bailey previously served as the
Global Chief Marketing Officer for Merrell Outdoors, overseeing
both product and consumer marketing with annual revenues of
US$600M. Prior to his tenure at Merrel, Jim served as President of
Red Bull Canada, playing an instrumental role in launching the Red
Bull brand in Canada and growing the business to $150M in annual
revenue with over 300 employees nationwide.
“I am very excited to be part of a company that is leading the
way in finding alternative solutions to traditional pharmaceuticals
with science based research and functional products,” commented Jim
Bailey. “My background in heavily regulated industries coupled with
my experience in the CPG space provides a great compliment to an
already talented and experienced advisory board.”
Mr. Bailey will champion the marketing, distribution and
commercialization of the Company’s Novoformulations-branded novel
delivery systems for the pharmaceutical, nutraceutical and
psychedelic medicine industries. Novoformulations, a 100 per-cent
owned subsidiary of Champignon, is presently working with ketamine,
anaesthetics and adaptogenics, as well as a host of pharmaceuticals
and natural molecules at a purpose-built good manufacturing
practice (GMP) and pharmaceutical (DIN) licensed facility located
in Quebec, Canada. There, the Company is actively formulating,
developing and working to commercialize bioavailable delivery
platforms, including: Transdermal (topical), intranasal and
sublingual.
About Champignon Brands Inc.
Champignon Brands Inc. (CSE: SHRM) is a research-driven company
specializing in the formulation of a suite of medicinal mushrooms
health products as well as novel ketamine, anaesthetics and
adaptogenic delivery platforms for the nutritional, wellness and
alternative medicine industries. Via its vertically integrated
alternative medicine product range, Champignon is pursuing the
development and commercialization of rapid onset treatments capable
of improving health outcomes, such as depression and post-traumatic
stress disorder (PTSD), as well as substance and alcohol use
disorders. Under a collaborative research agreement with the
University of Miami's Miller School of Medicine, the Company is
conducting preclinical studies and eventual human clinical trials,
with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with
PTSD or stand-alone PTSD. Champignon continues to be inspired by
sustainability, as its medicinal mushroom-infused SKUs are organic,
non-GMO and vegan certified. For more information, visit the
Company’s website at: https://champignonbrands.com/.
ON BEHALF OF THE BOARD OF DIRECTORS
W. Gareth Birdsall CEO & DirectorT: +1 (613)
967-9655E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Tyler Troup Circadian Group
E: SHRM@champignonbrands.com
FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy ScalabriniMaricom Inc.E: rs@maricom.ca T: (888)
585-MARI
The CSE and Information Service Provider have
not reviewed and does not accept responsibility for the accuracy or
adequacy of this release.
Forward-looking Information Cautionary
Statement
Except for statements of historic fact, this
news release contains certain "forward-looking information" within
the meaning of applicable securities law. Forward-looking
information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements are
based on the opinions and estimates at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking statements
including, but not limited to delays or uncertainties with
regulatory approvals, including that of the CSE. There are
uncertainties inherent in forward-looking information, including
factors beyond the Company’s control. There are no assurances that
the business plans for Champignon Brands described in this news
release will come into effect on the terms or time frame described
herein. The Company undertakes no obligation to update
forward-looking information if circumstances or management's
estimates or opinions should change except as required by law. The
reader is cautioned not to place undue reliance on forward-looking
statements. Additional information identifying risks and
uncertainties that could affect financial results is contained in
the Company’s filings with Canadian securities regulators, which
are available at www.sedar.com.
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Jan 2024 bis Jan 2025